Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.45 |
| ▸ | KDR | P35968 | 17/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.45 |
| ▸ | PRKDC | P78527 | 17/20 | 0.45 |
| ▸ | ABL1 | P00519 | 16/20 | 0.45 |
| ▸ | EGFR | P00533 | 16/20 | 0.45 |
| ▸ | HCK | P08631 | 16/20 | 0.45 |
| ▸ | SRC | P12931 | 16/20 | 0.45 |
| ▸ | MTOR | P42345 | 16/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 16/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617731 | 0.86 | PIK3CD (0.57) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17264223 | 0.82 | RET (0.46) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17090642 | 0.80 | BTK (0.55) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21057449 | 0.75 | KDM4E (0.52) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17265759 | 0.72 | BTK (0.52) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14617730 | 0.68 | RET (0.62) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17264222 | 0.68 | RET (0.46) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14617721 | 0.68 | BTK (0.57) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17090621 | 0.68 | BTK (0.71) | PIK3CDKDRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21057281 | 0.67 | KDR (0.43) | PIK3CDKDRPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PIK3CD 534/4885KDR 983/4885PIK3CA 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.